DCTH - Delcath Systems, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0710
-0.0090 (-11.25%)
At close: 3:53PM EDT
Stock chart is not supported by your current browser
Previous Close0.0800
Open0.0850
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0710 - 0.0850
52 Week Range0.0670 - 10.3000
Volume128,922
Avg. Volume124,896
Market Cap1.298M
Beta (3Y Monthly)-0.40
PE Ratio (TTM)N/A
EPS (TTM)-1.8790
Earnings DateSep 12, 2019 - Sep 16, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.00
Trade prices are not sourced from all markets
  • GlobeNewswireyesterday

    Delcath Systems Closes $20 Million Private Placement

    Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us” (DCTH) has closed on its previously announced private placement with gross proceeds of $20 million at a combined price of $1,000 per Unit. Each Unit consists of one preferred share initially convertible into 16,667 shares of common stock at an initial conversion price of $0.06 per share and a common stock purchase warrant. Each whole warrant entitles the holder to purchase one share of common stock at an initial exercise price of $0.06 for a period of five years from the date of the Company’s anticipated reverse stock split.

  • GlobeNewswire7 days ago

    Delcath Systems Announces $20 Million Private Placement

    Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us”) (DCTH) today announced that it has entered into a definitive agreement for gross proceeds of approximately $20 million at a combined price of $1,000 per Unit. Each Unit consists of one preferred share initially convertible into 16,667 shares of common stock at an initial conversion price of $0.06 per share and a common stock purchase warrant. Each whole warrant entitles the holder to purchase one share of common stock at an initial exercise price of $0.06 for a period of five years from the date of the Company’s anticipated reverse stock split.

  • GlobeNewswire3 months ago

    Results of Single Center Prospective Study on Delcath’s PHP Therapy Presented at ECIO 2019

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that results from a prospective phase 2 study conducted by Leiden University Medical Center (LUMC) in the Netherlands on the use of the Delcath Hepatic CHEMOSAT® Delivery System to treat patients with metastatic ocular melanoma with liver metastases were presented at the European Conference on Interventional Oncology (ECIO) annual meeting.

  • GlobeNewswire5 months ago

    Delcath Joins the Ocular Melanoma Community in Recognizing Rare Disease Day

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, highlights the experiences of patients with ocular melanoma as part of Rare Disease Day®—a global awareness campaign observed each year on February 28th. Delcath sponsors a global Registration clinical trial for Patients with Hepatic Dominant Ocular Melanoma called The FOCUS Trial. “Rare Disease Day is an opportunity for the global healthcare community to recognize the unmet medical needs among patients suffering from orphan diseases,” said Jennifer K. Simpson, Ph.D., MSN, CRNP President and CEO of Delcath.

  • GlobeNewswire5 months ago

    Delcath Announces Health Authority Approval for CHEMOSAT in Brazil

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company has received medical device approval for the CHEMOSAT® Hepatic Delivery System (CHEMOSAT) from the national health authority in Brazil. The approval of CHEMOSAT as a Class 3 medical device was issued by the Agência Nacional de Vigilância Sanitária (ANVISA), and permits the marketing and utilization of CHEMOSAT under the same percutaneous intra-arterial administration of melphalan hydrochloride to the liver with subsequent extracorporeal filtration of blood indication, as in Europe. To develop Brazilian market access for CHEMOSAT, Delcath intends to align with a local strategic partner.

  • GlobeNewswire5 months ago

    Delcath Announces Acceptance of Abstract for Oral Presentation at ECIO 2019

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces an abstract from a prospective phase 2 study conducted in the Netherlands of the use of the Delcath Hepatic CHEMOSAT® Delivery System to treat patients with metastatic ocular melanoma with liver metastases, has been accepted for oral presentation and as a poster at the European Conference on Interventional Oncology (ECIO) annual meeting. The abstract, Percutaneous hepatic perfusion with melphalan in patients with unresectable liver metastases from ocular melanoma using the Delcath System's second-generation hemofiltration system: a prospective phase II study, will be presented by T.S. Meijer and M.C. Burgmans, et al of the Leiden University Medical Center in the Netherlands.

  • GlobeNewswire7 months ago

    Delcath Announces Commercial Licensing Agreement for CHEMOSAT®

    Upfront and Milestone Payments Provide Additional Resources to Advance Clinical Development in the U.S. NEW YORK, Dec. 26, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the company has entered into a definitive licensing agreement for CHEMOSAT® commercialization in Europe with medac Gesellschaft für klinische Spezialpräparate mbH (medac), a privately held, multi-national pharmaceutical company based in Hamburg area, Germany. Founded in 1970, medac specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.

  • GlobeNewswire7 months ago

    Delcath Announces 4th Independent Safety Review of Registration Trial Data for Metastatic Ocular Melanoma: Recommended Continuation with no Trial Modification

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the independent Data Safety Monitoring Board (DSMB) of the Registration trial for Patients with Hepatic Dominant Ocular Melanoma (The FOCUS Trial) completed another pre-specified review of safety data for treated patients in the trial. In July, the Company announced that it has amended the protocol for the FOCUS trial, which is now enrolling as a single-arm, multi-center open label study. Safety data collected have not been modified as a result of the amendment, and safety data from both the randomized and single-arm protocols will be pooled in any analyses submitted to the Food & Drug Administration as part of a New Drug Application.

  • GlobeNewswire8 months ago

    Delcath Announces Third Quarter Fiscal 2018 Financial Results

    NEW YORK, Nov. 13, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces.